„ Letter to the Editor

Percutaneous coronary intervention to treat unprotected left main: Unmet needs

Marin Pavlov
Department of Cardiology, Dubrava University Hospital, Zagreb, Croatia

Correspondence to:

Marin Pavlov, MD, PhD,

Department of Cardiology, Dubrava University Hospital,

Avenija Gojka Šuška 6, 10000 Zagreb, Croatia,

phone: +38 599 236 02 86,

e-mail: marin.pavlov@gmail.com

Copyright by the Author(s), 2022

DOI: 10.33963/KP.a2022.0134

Received: May 19, 2022

Accepted: May 20, 2022

Early publication date: May 20, 2022

We read with much interest the article by Kovacevic et al. [1] about modern dilemmas in interventional treatment of the left main (LM) disease. The authors described clearly and provided solutions for imaging and functional assessment modalities, procedural issues, and options for overcoming hemodynamic instabilities during the procedure. However, some aspects of LM percutaneous coronary interventions (PCI) were left understated.

As reported by the authors, intravascular ultrasound (IVUS), in addition to the assessment of the intermediate stenosis significance, provides a morphological plaque evaluation. However, IVUS is poorly utilized (16.7% in our last cohort [2]), especially in predominantly acute PCI centers with a high percentage of ad hoc interventions (63.7% of the patients presented with acute coronary syndrome; 70.0% of the interventions were ad hoc in the same cohort). Yet, the data obtained by IVUS are crucial in foreseeing difficult procedures leading to suboptimal outcomes. Avoiding routine pre-interventional IVUS could elicit worse outcomes. Insight into calcium burden, eccentricity, and particularly nodularity often leads to a change in revascularization strategy. Interventional society is very much aware of the results of the two major LM studies [3, 4] with suboptimal results in PCI arms. The usage of IVUS in these studies was 77% and 72%. In the Nordic-Baltic-British Left Main Revascularization (NOBLE) trial substudy analysis, the usage of IVUS was associated with lower LM target lesion revascularization, although the differences in hard outcomes remained non-significant (5.1% vs. 11.6%; P = 0.01 [5]; in both studies IVUS was not used for determining the eligibility for PCI strategy, but for post-stenting optimization purposes). Thus, maximizing imaging usage in, preferably, all LM patients with chronic coronary syndrome, and in the majority of acute coronary syndrome patients, or at least in those without acute thrombotic lesions, should be our first goal. I would like the authors to share with readers their current practice and reflections on whether IVUS should be used in all LM PCI procedures.

Recent advances in the PCI strategy (wrist access, potent antiplatelet therapy, debulking devices, latest stent generations, insights into optimal bifurcation technics, options for hemodynamic support) vastly outnumber the advances in surgical strategy. Yet, the PCI strategy is still considered only in the case of patients with a low Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score or those refusing surgery. This “low SYNTAX” score often translates to “low-risk” patients, commonly signifying normal systolic function and an absence of significant comorbidity. Yet those at “high risk” or frail and elderly patients, as Kovacevic et al. [1] stated, could benefit from PCI supported by decongestive strategies such as Impella (Abiomed, Danvers, MA, USA) or iVAC 2L (PulseCath, Amsterdam, The Netherlands), by simply avoiding surgery. How many patients with successful surgery and unfavorable postoperative course have we seen? Should we look up to our older patients with severe aortic stenosis that we now regularly treat percutaneously? Is it fair time for new noble studies in excelling field of interventional LM revascularisation? I wonder about the opinion and current practice of the authors in the field of LM PCI for high-risk patients with intermediate and high SYNTAX scores; how do the authors translate current recommendations into everyday workflow?

Article information

Conflict of interest: MP is a LM interventionalist.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

  1. Kovacevic M, Burzotta F, Srdanovic I, et al. Percutaneous coronary intervention to treat unprotected left main: Common (un-answered) challenges. Kardiol Pol. 2022; 80(4): 417428, doi: 10.33963/KP.a2022.0078, indexed in Pubmed: 35545858.
  2. Pavlov M, Babić Z, Trbušić M, et al. Left main stenosis: how do we treat it? Cardiol Croat. 2020; 15(34): 46, doi: 10.15836/ccar2020.46.
  3. Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019; 381(19): 18201830, doi: 10.1056/nejmoa1909406, indexed in Pubmed: 31562798.
  4. Mäkikallio T, Holm NR, Lindsay M, et al. NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016; 388(10061): 27432752, doi: 10.1016/S0140-6736(16)32052-9, indexed in Pubmed: 27810312.
  5. Ladwiniec A, Walsh SJ, Holm NR, et al. Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy. EuroIntervention. 2020; 16(3): 201209, doi: 10.4244/EIJ-D-19-01003, indexed in Pubmed: 32122821.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl